Pharma News, 2018

LONDON (Reuters) - Pfizer lost the final round in a long-running patent battle in Britain on Wednesday after the country’s highest court ruled against it in a case involving its $5 billion-a...

Basel, November 11, 2018 - Novartis announced today results of the landmark PIONEER-HF trial showing that in-hospital initiation of Entresto tablets provided superior benefit compared to enalapril-a...

AstraZeneca has agreed to sell US rights to Synagis (palivizumab) used for the prevention of serious lower respiratory tract infection (LRTI) caused by respiratory syncytial virus (...

EMD Serono wants to know what’s on the minds of multiple sclerosis patients and their loved ones.

Last month, AstraZeneca and Merck’s Lynparza posted big-time ovarian cancer data, and regulators are taking note.

Antimicrobial resistance is a major threat to health and human development, affecting our ability to treat a range of infections.

AstraZeneca today announced positive full results from the DECLARE-TIMI 58 cardiovascular (CV) outcomes trial (CVOT) for Farxiga (dapagliflozin).

Investigational Medicinal Product (IMP) Gammora is a synthetic peptide compound derived from the HIV enzyme integrase, which is responsible for inserting the virus's genetic material into ...

(Reuters) - Theravance Biopharma Inc and partner Mylan NV on Friday won U.

(Reuters) - Updated U.

A chemical that highlights tumour cells has been used by surgeons to help spot and safely remove brain cancer in a trial presented by a University of Bristol academic at the 2018 NCRI Cancer Conferenc...

Recro Pharma was granted a March 2019 PDUFA date for its non-opioid pain drug after providing the FDA with additional data and answering manufacturing questions raised in a complete response letter.